Based on the Centessa Pharmaceuticals PLC ADR stock forecast from 6 analysts, the average analyst target price for Centessa Pharmaceuticals PLC ADR is USD 21.00 over the next 12 months. Centessa Pharmaceuticals PLC ADR’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Centessa Pharmaceuticals PLC ADR is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Centessa Pharmaceuticals PLC ADR’s stock price was USD 17.04. Centessa Pharmaceuticals PLC ADR’s stock price has changed by +6.50% over the past week, +12.48% over the past month and +160.55% over the last year.
Analyst Ratings
Target Price Action
Rating Action
Analyst
Rating
Price
Date
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Download Confirmation
Premium customers can only download records visible on the current page view, while Platinum customers can download the first 1000 records.
Paid-only feature
CSV downloads are only available for paying customers.
Thank you for Sharing your Stock Targets for CNTA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
